CD8A and neoplasm: MRX34 treatment in 344SQ mouse model resulted in increased tumor-infltrating CD8+ cells and decreased tumor-infltrating PD1+ T-cells, macrophages and T-regulatory cells, and finally delayed tumor growth [103].